سیویلیکا - ناشر تخصصی مقالات کنفرانس ها و ژورنال ها گواهی ثبت مقاله در سیویلیکا CIVILICA.com

عنوان مقاله:

Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions; Comment on "Problems and "Promises of Health Technologies: The Role of Early Health Economic Modelling

محل انتشار:

مجله بین المللی سیاست و مدیریت بهداشت, دوره 9, شماره 8 (سال: 1399)

تعداد صفحات اصل مقاله: 4

نویسندگان:

Nadine K. Zawadzki - Schaeffer Center for Health Policy and Economics, Department of Pharmaceutical and Health Economics, School of Pharmacy,
University of Southern California, Los Angeles, CA, USA

Joel W. Hay - USC Clinical Economics Research and Education Program (CEREP), Los Angeles, CA, USA

خلاصه مقاله:

With their article, Grutters et al raise an important question: What do successful health technology assessments (HTAs) look like, and what is their real-world utility in decision-making? While many HTAs are published in peer-reviewed journals, many are considered proprietary and their attributes remain confidential, limiting researchers' ability to answer these questions. Models for economic evaluations like cost-effectiveness analyses (CEAs) synthesize a wide range of evidence, are often statistically and mathematically sophisticated, and require untestable assumptions. As such, there is nearly universal agreement among researchers that enhancing transparency is an important issue in health economic modeling. However, the definition of transparency and guidelines for its implementation vary. Model registration combined with a linked database of model-based economic evaluations has been proposed as a solution, whereby registered models and their accompanying technical and nontechnical documentation are sourced into a single publicly-available repository, ideally in a standardized format to ensure consistent and complete representation of features, code, data sources, results, validation exercises, and policy recommendations. When such a repository is ultimately created, modelers will not have to reinvent the wheel for every new drug launched or new treatment pathway. These more open and transparent approaches will have substantial implications for model accuracy, reliability, and validity, improving trust and acceptance by healthcare decision-makers

كلمات كليدى:

Health Technology Assessment, Economic Modeling, Cost-Effectiveness, Transparency

لینک ثابت مقاله در پایگاه سیویلیکا:

https://civilica.com/doc/2048192

